Pilot Study of Ponatinib in Biliary Cancer Patients With FGFR2 Fusions
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Jan 2018
At a glance
- Drugs Ponatinib (Primary)
- Indications Biliary cancer; Cholangiocarcinoma
- Focus Therapeutic Use
- 18 Jan 2018 Trial design presented at the Gastrointestinal Cancers Symposium.
- 29 Sep 2017 Status changed from suspended to active, no longer recruiting.
- 18 Jul 2017 Status changed from recruiting to suspended.